Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer.
Aged
Alcohol Drinking
/ epidemiology
Biomarkers, Tumor
/ genetics
Case-Control Studies
Chile
/ epidemiology
Cigarette Smoking
/ epidemiology
Cyclooxygenase 2
/ genetics
Epidermal Growth Factor
/ genetics
ErbB Receptors
/ genetics
Female
Genetic Predisposition to Disease
Humans
Laryngeal Neoplasms
/ epidemiology
Male
Middle Aged
Polymorphism, Single Nucleotide
Risk Factors
Squamous Cell Carcinoma of Head and Neck
/ epidemiology
Tumor Suppressor Protein p53
/ genetics
Biomarkers
EGF
EGFR
Genomics
Laryngeal cancer
PTGS2
Polymorphism
TP53
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
29 05 2020
29 05 2020
Historique:
received:
25
04
2019
revised:
07
04
2020
accepted:
16
04
2020
pubmed:
28
4
2020
medline:
30
3
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Laryngeal squamous cell carcinoma (LSCC) is a highly disabling disease to the patient, affecting speech, swallowing and respiratory skills. Smoking and alcohol abuse are principal risk factors linked to this disease. Genetic factors can be involved in carcinogenesis by controlling the cell cycle, cell survival, angiogenesis, and invasiveness. Single nucleotide polymorphisms (SNPs) involving specific genes could modulate the risk of LSCC related to known carcinogens by modifying cellular responses, but not all genetic associations are known. In a case-control study, we assess the associations between cyclooxygenase-2 (COX2), epidermal growth factor (EGF), EGF receptor (EGFR), and tumor suppressor P53 SNPs on the risk of LSCC development in the Chilean population. A total of 85 LSCC patients and 95 healthy volunteers were recruited. SNPs genotype were analyzed from genomic DNA by Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) and associations were estimated by odds ratios (ORs) using unconditional logistic regressions. A significant association between COX2 and TP53 SNP and LSCC risk was found, with an OR = 3.27 for COX2 c.-1329A>G (rs689466) SNP, and an OR = 1.94 for TP53 c.215C>G, Pro72Arg (rs1042522) SNP. These findings suggest that COX2 c.-1329A>G and TP53 c.215C>G (Pro72Arg) SNPs may be risk factors for LSCC. Through this research, we identify two low penetrance genetic variants that may be evaluated as novel biomarkers for this disease, in South American Mestizo populations.
Identifiants
pubmed: 32338278
pii: 222773
doi: 10.1042/BSR20191188
pmc: PMC7201556
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Epidermal Growth Factor
62229-50-9
Cyclooxygenase 2
EC 1.14.99.1
PTGS2 protein, human
EC 1.14.99.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 The Author(s).
Références
J Cancer Res Clin Oncol. 2009 Feb;135(2):313-8
pubmed: 18726117
Genet Mol Res. 2015 Apr 28;14(2):4282-90
pubmed: 25966200
Nat Rev Cancer. 2007 Aug;7(8):599-612
pubmed: 17646865
Int J Cancer. 2004 Jan 10;108(2):196-9
pubmed: 14639602
Mol Cell Biol. 1999 Feb;19(2):1092-100
pubmed: 9891044
J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
pubmed: 10413421
Br Med Bull. 1991 Jan;47(1):87-98
pubmed: 1863851
Gynecol Oncol. 2005 Mar;96(3):736-40
pubmed: 15721419
Onco Targets Ther. 2014 Nov 28;7:2197-204
pubmed: 25506224
Gastroenterology. 2005 Aug;129(2):565-76
pubmed: 16083713
Lancet. 2002 Feb 2;359(9304):397-401
pubmed: 11844511
Lancet Oncol. 2003 Oct;4(10):605-15
pubmed: 14554238
Environ Mol Mutagen. 2014 Mar;55(2):134-44
pubmed: 24519899
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
PLoS One. 2012;7(4):e34422
pubmed: 22545084
Semin Cell Dev Biol. 2014 Apr;28:2-11
pubmed: 24513230
Mutat Res. 2009 Apr 26;663(1-2):52-9
pubmed: 19428370
Arq Gastroenterol. 2014 Apr-Jun;51(2):79-83
pubmed: 25003256
N Am J Med Sci. 2013 Mar;5(3):202-6
pubmed: 23626956
Nat Med. 2002 Mar;8(3):289-93
pubmed: 11875501
Neoplasia. 2012 Jul;14(7):634-43
pubmed: 22904680
Asian J Androl. 2006 May;8(3):349-55
pubmed: 16625286
Mol Biol Rep. 2014;41(4):2667-70
pubmed: 24452716
Br J Pharmacol. 2001 Nov;134(6):1137-50
pubmed: 11704632
BMC Cancer. 2014 Mar 14;14:187
pubmed: 24629046
Am J Epidemiol. 2001 May 15;153(10):1016-20
pubmed: 11384958
Epidemiol Rev. 1997;19(1):33-43
pubmed: 9360900
World J Gastroenterol. 2011 Jan 28;17(4):488-92
pubmed: 21274378
Gut Liver. 2012 Jul;6(3):321-7
pubmed: 22844559